Normal view MARC view ISBD view

The aquatic fate of triclopyr in whole-pond treatments. [electronic resource]

By:

Petty, D G

Contributor(s):

Producer: 20020403Description: 764-75 p. digitalISSN:

1526-498X

Subject(s):

Online resources:

Available from publisher's website

In: Pest management science vol. 57

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

There are no comments on this title.

to post a comment.

Back to results

1021 Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries.
by Mandinov, L
1022 Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
by Kontoghiorghes, George J
1023 Design of the Trial to Assess Chelation Therapy (TACT).
by Lamas, Gervasio A
1024 Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice.
by Nieuwenhuizen, Laurens
1025 Novel oral detoxification of mercury, cadmium, and lead with thiol-modified nanoporous silica.
by Sangvanich, Thanapon
1026 Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
by Piccioni, Maria Grazia
1027 Zinc supplementation of chelation therapy in saturnism. Preliminary study.
by Bădulici, S
1028 Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
by Cases, A
1029 Alteration in the organ distribution of iron by truncated transferrin: implications for iron chelation therapy.
by Li, L
1030 Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
by Chan, Yu-Leung
1031 Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
by Meo, Anna
1032 Iron chelation therapy in the management of thalassemia: the Asian perspectives.
by Viprakasit, Vip
1033 Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
by Liu, Gang
1034 Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
by Aydinok, Yesim
1035 EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
by Born, Tammy
1036 Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
by Kalpatthi, Ram
1037 Current use of chelation in American health care.
by Wax, Paul M
1038 Management of iron overload in hemoglobinopathies.
by Allali, S
1039 Labile plasma iron as an indicator of patient adherence to iron chelation treatment.
by Steinberg-Shemer, Orna
1040 Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis.
by Borgna-Pignatti, C